Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An adenocarcinoma that arises from the fallopian tube and resembles the endometrioid adenocarcinoma of the uterus. It usually has a favorable prognosis.
Biomarker and diagnostic research for fallopian tube endometrioid adenocarcinoma has been reported in the published literature.
18 clinical trials registered, 1 recruiting. Interventions under study include drug therapy, procedural interventions, biologic therapy, and other interventions. Pipeline includes 3 PHASE3, 10 PHASE2, 4 PHASE1. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06639074](https://clinicaltrials.gov/study/NCT06639074) |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 8:43 AM UTC
Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial |
PHASE2 |
Mayo Clinic |
RECRUITING |
29 publications have been identified in PubMed for fallopian tube endometrioid adenocarcinoma. Research spans Case Report / Case Series (28%), Clinical Trial Publication (24%), and Basic Science / Preclinical (17%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 8 | 28% |
Clinical study results | 7 | 24% |
Laboratory research | 5 | 17% |
Testing and diagnosis research | 3 | 10% |
Disease patterns and progression | 3 | 10% |
Research summaries | 2 | 7% |
Other research | 1 | 3% |
McHenry A (2026). [PMID: 40769949](https://pubmed.ncbi.nlm.nih.gov/40769949/). *Histopathology*. [Case Report / Case Series]
Jorgensen A (2026). [PMID: 41804072](https://pubmed.ncbi.nlm.nih.gov/41804072/). *Advanced biology*. [Case Report / Case Series]
Lengyel K (2026). [PMID: 41808247](https://pubmed.ncbi.nlm.nih.gov/41808247/). *The American journal of surgical pathology*. [Basic Science / Preclinical]
Scott CL (2026). [PMID: 41786760](https://pubmed.ncbi.nlm.nih.gov/41786760/). *Nature reviews. Disease primers*. [Review / Meta-Analysis]
Fukuda N (2026). [PMID: 41430003](https://pubmed.ncbi.nlm.nih.gov/41430003/). *International journal of clinical oncology*. [Epidemiology / Natural History]
Zhao X (2025). [PMID: 40350708](https://pubmed.ncbi.nlm.nih.gov/40350708/). *Journal of gynecologic oncology*. [Review / Meta-Analysis]
Ozcivit Erkan IB (2025). [PMID: 39641624](https://pubmed.ncbi.nlm.nih.gov/39641624/). *International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics*. [Case Report / Case Series]
Liou WS (2025). [PMID: 41575336](https://pubmed.ncbi.nlm.nih.gov/41575336/). *Journal of gynecologic oncology*. [Epidemiology / Natural History]
Katayama Y (2025). [PMID: 39716847](https://pubmed.ncbi.nlm.nih.gov/39716847/). *Cancer science*. [Case Report / Case Series]
Cao Q (2025). [PMID: 41216238](https://pubmed.ncbi.nlm.nih.gov/41216238/). *CytoJournal*. [Case Report / Case Series]
AI-curated news mentioning fallopian tube endometrioid adenocarcinoma
Updated Jul 21, 2026
A case report details a fallopian tube nontuberculous mycobacterial infection caused by Mycobacterium abscessus, which mimicked fallopian tube carcinoma. This finding highlights the need for differential diagnosis in similar cases.
A case report details the occurrence of primary endometrioid adenocarcinoma of the vagina following total hysterectomy for adenomyosis. This finding contributes to the understanding of rare cancer presentations post-surgery.